PCI Evolution in Infiltrative Diseases

Infiltrative diseases (ID) consist of a heterogeneous series of genetic conditions that cause infiltration and extracellular deposits which alter the diverse systems and organs affected.   

ATC en enfermedades infiltrativas

Amyloidosis, sarcoidosis and hemochromatosis affect the heart, altering the myocardium and the conduction system. 

PCI is often used at present to treat heart disease, and some of these patients present ID. Different analysis suggest that PCI might evolve differently vs. patients with no ID; however, it has not yet been thoroughly looked into. 

There was a retrospective analysis, from January 2016 to December 2020, including 2,360,860 patients; 7,855 (0.77%) with ID (amyloidosis 990, sarcoidosis 5,260 and hemochromatosis 1,625).

Read also: TAVR in Low Risk Patients: 10 Year Evolution.

Primary end point was the post-PCI combination of inhospital death, stroke and major bleeding. 

Patients with amyloidosis were older and had more comorbidities vs. sarcoidosis and hemochromatosis patients. 

Primary end point resulted more frequent in amyloidosis patients (1.6% vs. 1.1% vs. 1.18%, OR 1.6; CI del 95%, 1.1-2.44; P= .02 for amyloidosis, sarcoidosis and hemochromatosis, respectively); they also showed higher mortality (1.9% vs. 1.09% vs. 0.72%, P<0.05), and stroke (4% vs. 0% vs. 2.28%, P<0.05), but there were no significant differences in major bleeding (2.2% vs. 0.96% vs. 1.03%, p>0.05).

Read also: Sub-Analysis of the REVIVED-BCIS2: Myocardial Viability Changes Prognosis in Ischemic Cardiomyopathy Revascularization?

The cost of hospitalization and hospital stay was higher in patients with amyloidosis. 

Conclusion

Amyloidosis was associated with worse evolution after PCI, including higher inhospital mortality, intra and post procedural stroke, and socioeconomic cost. We highlight the need for a multidisciplinary approach for better assessment and further research, to better guide the screening and management strategy of these patients. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical Outcomes of Percutaneous Coronary Intervention in Amyloidosis, Sarcoidosis, and Hemochromatosis.

Reference: Bilal Hussain, et al. JSCAIhttps://doi.org/10.1016/j.jscai.2023.101267. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...

New Balloon-Expandable Aortic Valve: 30-Day Outcomes in Patients with Small Aortic Annulus

As transcatheter aortic valve implantation (TAVI) continues to expand toward younger patients with longer life expectancy, factors such as valve hemodynamic performance, durability, and...